IFO is a nitrogen mustard agent and the cell cycle class of melted non-specific drugs, as the isomers of cyclophosphamide.Experimental study of ifosfamide, first synthesized by German pharmaceutical company Asta on transplanted tumor in mice Lewis lung cancer and sarcoma 180 tumor growth and the role of different levels, and a dose-effect relationship.
Experimental study of ifosfamide L1210 leukemia in early animal life extension rate, the optimal dose and administration schedule related. IFO antitumor activity than CTX, toxic than cyclophosphamide, a variety of human tumors with good results. Good oral absorption, bioavailability close to 100%, because of its severe side effects of bleeding bladder inflammation limits the clinical use until 1981 Brocked synthesis of urinary tract protective agent Mesna (U.S. Secretary is satisfied), it can be widely used, 1988 by FDA in the United States.
By 1991, clinical trial in China market. After the rapid distribution of intravenous IFO to each organization, activity of liver drug to be generated by different play phosphorus amide nitrogen mustard anti-tumor effect, similar to the mechanism and nitrogen mustard. IFO concentration of anti-cancer effect and under certain duration related.
Experimental study of ifosfamide, conventional dose 1.6–2.4g/ml, consecutive 3 – 5 days of drug half-life of about 7h, about 55% – 60% from the urine, and 15% for the prototype discharge; – second high dose 3.8–5.0/ml, half-life of 15h, 80% from the urine, of which 50% – 55% of the prototype. Therefore, the sub-dose can obtain better biological effects.